V-Bio Ventures. (3/31/22). "Press Release: V-Bio Ventures Raises EUR 110 Million for its Second Fund and Expands Team". Ghent.

	Organisation	V-Bio Ventures Fund 2 (V-Bio Fund 2)
	Group	V-Bio Ventures
	Organisation 2	Merus N.V. (Nasdaq: MRUS)
	Group	Merus (Group)
	Product	fund, biotech / life sciences
	Product 2	BIOTECH
	Index term	V-Bio Ventures–SEVERAL: investment, 202203 final closing with additional €32m of V-Bio Ventures Fund 2 bringing total fund size to €110m
	Person	Takke, Christina (V-Bio Ventures 201511 Managing Partner + Co-Founder before Forbion Capital Partners)
	Person 2	Broekaert, Willem (V-Bio Ventures 201511 Managing Partner + Co-Founder)

V-Bio Ventures announced the final closing of its second fund, V-Bio Fund 2, having raised EUR 110 million euro and exceeding its target of EUR 100 million.

Together with their first fund, V-Bio Fund 1, V-Bio Ventures will have over EUR 185 million under management, putting it in a very good position to fund promising innovative companies. Almost all limited partners of their first fund are participating in this second fund, as are multiple new investors. V-Bio Ventures is a venture capital company that focuses specifically on the segment of young pioneering biotech companies and its strategy to invest in transformational companies in the medical and agricultural sector will remain unchanged in this second fund. V-Bio Fund 2 will also maintain its fruitful relationship with VIB, Europe’s leading life sciences institute, to access deals from the renowned research center that has spun out multiple successful biotech companies such as Ablynx.

V-Bio Ventures is expanding their team from seven to nine experienced investment professionals with a scientific background and a wealth of experience from biotech companies and investment funds. Shelley Margetson joined the fund as Managing Partner, bringing her expertise as senior executive in multiple European biotechnology companies, including Nasdaq-listed Merus (MRUS). In addition to expanding the team, Ward Capoen, who has been with V-Bio Ventures since the start of the first fund, is being promoted to Partner.

Recent portfolio successes of V-Bio Ventures include Syndesi Therapeutics, which was acquired earlier this year by AbbVie for up to $1bn, as well as Agomab and Precirix having raised EUR 63m and 80m respectively from international investment syndicates. Since its inception in 2015 V-Bio Ventures has invested in nineteen companies, has co-created seven of them, and has helped to advance eight therapies into clinical development and closer to patients.

Christina Takke and Willem Broekaert, Founding Managing Partners of V-Bio Ventures: “We are extremely pleased to have received the confidence of both existing and new investors and look forward to continuing our proven strategy to invest early in new or young ventures based on outstanding science and to support their management teams through the initial value creating milestones.”

About V-Bio Ventures

V-Bio Ventures (www.v-bio.ventures) is an independent venture capital firm, specialized in developing and financing young, innovative life sciences companies. V-Bio Ventures was founded in 2015 and works closely with Belgium-based VIB, one of the world’s leading research institutes in the life sciences. The fund invests across Europe in high growth potential start-ups targeting transformational innovations in the biotech, pharmaceutical and agricultural sectors.

We are a life sciences fund investing throughout Europe in start-up and early-stage companies with high growth potential. Our articles cover investment-related topics in life sciences, including innovation trends, the latest business themes and exciting updates on our portfolio companies.

Record changed: 2023-06-05